Channels - PACIFIC‐5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC :: FRELIP Discovery

Similar Items: PACIFIC‐5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC

Quick Look
Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab
Quick Look
The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy
Quick Look
Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study
Quick Look
Clinical Factors Associated With Non‐Completion of Durvalumab Maintenance Therapy After Chemoradiotherapy in Patients With Locally Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study
Quick Look
Impact of Multimodal Oncological Therapy on Survival and Local Control in Unresectable Perihilar Cholangiocarcinoma
Quick Look
Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications
Quick Look
Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer
Quick Look
Association of Preoperative Prognostic Nutritional Index on Long‐Term Outcomes and Postoperative Complications of Stage I–III Colorectal Cancer
Quick Look
Impact of Targeted Immune Checkpoint Inhibitor Adjuvant Therapy on Recurrence-Free Survival and Functional Recovery in Stage III Tongue Cancer Patients: A Retrospective Cohort Study
Quick Look
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France
Quick Look
Disparities in Depression Among Older Asian, Native Hawaiian, and Pacific Islander Patients With Lung Cancer
Quick Look
Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC
Quick Look
Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review
Quick Look
Association of the PD‐L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer
Quick Look
Prognostic Impact of the Systemic Immune-Inflammation Index in Unresectable Hepatocellular Carcinoma Undergoing Second-Line Combination Therapy: A Multicenter Study
Quick Look
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management
Quick Look
Refining the boundaries of the nodal CTV in the middle neck for nasopharyngeal carcinoma
Quick Look
The hsa_circ_0070354/miR‐4322/RAB3B Axis Facilitates the Carcinogenesis and Development of Non‐Small Cell Lung Cancer (NSCLC)
Quick Look
Withstanding the test of time for patients in oncology clinical trials
Quick Look
Tumor Necrosis on Routine Pretreatment CT as a Potential Prognostic Marker in Advanced NSCLC Treated With Immune Checkpoint Inhibitor Monotherapy: A Two‐Center Retrospective Study
Quick Look
Survival of Hematologic Malignancy In Patients With Early‐Stage Chronic Kidney Disease (SHIP‐CKD)
Quick Look
Sequential EGFR T790M, MET c.3010C>G‐Associated Exon 14 Alteration, and RET‐CCDC6 Fusion in EGFR‐Mutant NSCLC: A Case Report
Quick Look
Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia
Quick Look
Comparison of complications between laparoscopic and open abdominal approaches in morbidly obese patients with early-stage endometrial carcinoma